Clinical Outcome of Radiation Therapy for Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphomas

Abstract

role of radiation therapy in localized (Ann Arbor stage I/II) NGNO MALT lymphoma. Materials/Methods: We retrospectively reviewed 47 patients who were histologically diagnosed as NGNO MALT lymphoma with Ann Arbor stage I/II from Feb 1993 to Oct 2012. Primary sites were head and neck (n Z 19), gastrointestinal tract (n Z 8), lung (n Z 7), and others. Their median age was 53 years (range 15-83 years). Forty-one patients had relatively good performance status (Eastern Cooperative Oncology Group performance score 1). Twenty-nine patients received radiation therapy (RT) containing treatment (14 RT alone, 11 surgery + RT, 2 chemotherapy (CTx) + RT, 2 surgery + RT + CTx) with a median RT dose of 30.6 Gy (22.5 to 45 Gy). Other 18 patients did not receive RT (9 surgery alone, 5 surgery + CTx, 4 CTx alone). Results: Median follow-up time was 45.6 months (range 4.8-224.5 months). The estimated 5-year progression-free survival (PFS) and overall survival rates were 61% and 92%, respectively. Among the stage I/II patients, 29 patients who received RT all achieved complete remission (CR) and showed significantly higher 5-year PFS than who did not receive RT (82% vs 34%; p Z 0.003). Four patients among these 29 patients experienced out-field relapse, which were well salvaged by RT (3 patients) or CTx (1 patient), and there was no in-field relapse. Ten out of 18 patients (61%) who did not receive RT with stage I/II achieved CR, and 11 out of these 18 patients have relapsed while 4 patients progressed into diffuse large B-cell lymphoma. Three of them who showed high grade transformation died within 3 months since relapse. Conclusions: In localized NGNO MALT lymphoma, low dose RT resulted in excellent outcome and relapses out of RT field were also successfully salvaged by RT. Early use of RT should be considered in localized NGNO MALT lymphoma and should be applied as a preferred treatment modality in case of localized relapse. Author Disclosure: J. Lee: None. K. Kim: None. J. Cho: None. C. Suh: None.